IRIS
CARACCIOLO, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 802
EU - Europa 510
AS - Asia 301
Continente sconosciuto - Info sul continente non disponibili 7
AF - Africa 4
OC - Oceania 3
SA - Sud America 3
Totale 1.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 786
IT - Italia 355
SG - Singapore 205
CN - Cina 61
GB - Regno Unito 48
DE - Germania 30
SE - Svezia 27
CA - Canada 15
HK - Hong Kong 13
IN - India 13
NL - Olanda 11
FI - Finlandia 8
FR - Francia 8
EU - Europa 7
AT - Austria 5
RU - Federazione Russa 5
ES - Italia 4
JP - Giappone 4
AU - Australia 3
BR - Brasile 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
EG - Egitto 2
IR - Iran 2
UA - Ucraina 2
ZA - Sudafrica 2
BD - Bangladesh 1
CL - Cile 1
EE - Estonia 1
GR - Grecia 1
MX - Messico 1
MY - Malesia 1
PK - Pakistan 1
RO - Romania 1
Totale 1.630
Salva come PNG Salva come JPEG
Città #
Chandler 152
Singapore 108
Santa Clara 59
Chicago 47
Catanzaro 44
Lawrence 44
Princeton 44
London 43
Milan 40
Ashburn 38
Naples 19
Wilmington 18
Beijing 15
Rome 14
Des Moines 13
Ottawa 13
Parma 12
Hong Kong 10
Boardman 9
Cosenza 8
Ercolano 8
Helsinki 8
Los Angeles 8
Redwood City 8
San Nicola Manfredi 8
Santo Stefano di Rogliano 8
Melito di Porto Salvo 6
Munich 6
Afragola 5
Catania 5
Guangzhou 5
Settingiano 5
Shanghai 5
Brescia 4
Decollatura 4
Hanover 4
Jiaxing 4
Mountain View 4
Pune 4
Redmond 4
Seattle 4
Acquaviva delle Fonti 3
Ahmedabad 3
Berlin 3
Castrovillari 3
Frankfurt am Main 3
Mileto 3
Palermo 3
Paola 3
Reggio Calabria 3
San Antonio 3
Treviso 3
Washington 3
6th of October City 2
Agrigento 2
Andover 2
Assago 2
Bologna 2
Brighton 2
Buffalo 2
Campobello di Licata 2
Cape Town 2
Ceglie Del Campo 2
Council Bluffs 2
Delhi 2
Esslingen am Neckar 2
Gesuiti 2
Grottaglie 2
Hefei 2
Leawood 2
Madrid 2
New York 2
Nuremberg 2
Olomouc 2
Paris 2
Romainville 2
San Jose 2
Serra San Bruno 2
Shenzhen 2
Sorrento 2
Vallefiorita 2
Vigliano Biellese 2
Ann Arbor 1
Apo 1
Arnhem 1
Aversa 1
Baotou 1
Bari 1
Belovo 1
Bern 1
Bisignano 1
Byron 1
Canberra 1
Changchun 1
Chemnitz 1
Clearwater 1
Cutro 1
Delta Junction 1
East Lansing 1
Fairfield 1
Totale 979
Salva come PNG Salva come JPEG
Nome #
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 73
miR-22 suppresses DNA ligase III addiction in multiple myeloma 73
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 60
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 58
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 52
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 51
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 47
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 47
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 45
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 41
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 39
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 38
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 38
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 36
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 35
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 35
Mir-221/222 are promising targets for innovative anticancer therapy 35
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 35
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 34
Mmrf-commpass data integration and analysis for identifying prognostic markers 34
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 33
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 32
Pharmacogenomics biomarker discovery and validation for translation in clinical practice. 32
null 31
From single level analysis to multi-omics integrative approaches: A powerful strategy towards the precision oncology 30
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 30
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 29
Integration of DNA Microarray with Clinical and Genomic Data 29
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 28
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 28
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 27
Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats 26
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario 25
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes 24
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 23
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 23
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives 22
The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma 22
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma 22
Mirnas and lncrnas as novel therapeutic targets to improve cancer immunotherapy 22
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 21
Alternative non-homologous end-joining: Error-prone dna repair as cancer’s achilles’ heel 21
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 20
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 18
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity 17
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma 15
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells 14
From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology 14
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma. 14
Tools in Pharmacogenomics Biomarker Identification for Cancer Patients 14
An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma 13
Synthetic miR-22 impairs NHEJ repair sensistizing multiple myeloma cells to bortezomib-induced BRCAness 13
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts 13
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches 13
The potential role of miRNAs in multiple myeloma therapy 12
The potential role of miRNAs in multiple myeloma therapy 12
Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment. 11
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity 11
Targeting oncogenic pri-miR-17-92 in multiple myeloma: molecular findings and therapeutic potential 11
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 9
UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma 9
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity 8
Frontline therapy CLL without 17p del/p53 aberrations: systematic review and Bayesian network meta-analysis 7
TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects 5
Totale 1.759
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.953
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.953
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 0 0 0 0 0 0 0 0 0 8 15
2020/2021132 4 2 9 10 12 9 11 10 25 20 15 5
2021/2022179 4 0 0 27 7 5 11 30 37 31 24 3
2022/2023541 95 29 32 21 64 38 6 39 76 54 68 19
2023/2024320 86 32 36 22 16 83 7 6 1 5 10 16
2024/2025538 88 26 29 37 59 132 39 45 70 10 3 0
Totale 1.759